anti-BCMA CAR-T (Zhujiang Hospital)

anti-BCMA CAR-T (Zhujiang Hospital) is an autologous chimeric antigen receptor (CAR) T-cell therapy developed by Zhujiang Hospital for the treatment of relapsed or refractory multiple myeloma. The therapy involves the genetic modification of a patient's own T cells to express a CAR that specifically targets the B-cell maturation antigen (BCMA), a protein that is highly and nearly universally expressed on the surface of malignant plasma cells. Once these engineered T cells are re-infused into the patient, they recognize and bind to BCMA-expressing myeloma cells, triggering a cytotoxic immune response that leads to tumor cell lysis. This specific CAR-T candidate is part of a broader clinical research program at Zhujiang Hospital (associated with trial NCT03271632) that explores various antigenic targets in multiple myeloma, including CD138, CD38, and CD56, to optimize therapeutic outcomes in patients who have failed standard treatments.

Other names

BCMA-targeted CAR-T cellsanti-BCMA chimeric antigen receptor T-cellsanti-BCMA CAR-T-Zhujiang Hospital-multiple myeloma